Rocket Pharmaceuticals (RCKT) Accumulated Depreciation (2014 - 2026)

Rocket Pharmaceuticals has disclosed Accumulated Depreciation across 13 years of filings, most recently posting $30.7 million for Q1 2026.

• Accumulated Depreciation for Q1 2026 came in at $30.7 million, up 29.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.7 million (up 29.64% YoY), and the FY2025 annual result was $29.1 million, up 37.03% from the prior year.
• Accumulated Depreciation came in at $30.7 million for Q1 2026 at Rocket Pharmaceuticals, up from $29.1 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $30.7 million in Q1 2026 to a low of $6.0 million in Q1 2022.
• The 5-year median for Accumulated Depreciation is $15.7 million (2024), against an average of $17.0 million.
• Across the five-year window, Accumulated Depreciation soared 120.11% in 2022 and increased 29.64% in 2026, its largest moves.
• Rocket Pharmaceuticals' Accumulated Depreciation stood at $9.1 million in 2022, then soared by 54.32% to $14.0 million in 2023, then jumped by 51.46% to $21.3 million in 2024, then jumped by 37.03% to $29.1 million in 2025, then climbed by 5.52% to $30.7 million in 2026.
• The last three Accumulated Depreciation figures came in at $30.7 million (Q1 2026), $29.1 million (Q4 2025), and $27.4 million (Q3 2025), per Business Quant data.